IND stage candidate for the treatment of hematologic and solid tumors

KD5170 is a potent, orally administered, first-in-class non-hydroxamate inhibitor of histone deacetylase (HDAC).

KD5170 demonstrates significant anti-tumor activity in murine xenograft models of colon cancer, lung cancer, and multiple myeloma. Preliminary non-GLP toxicology studies have demonstrated a safety profile that supports continued development.

Kalypsys is currently targeting a 3Q07 IND submission.

KD5170 Fact Sheet